Quick Answer
LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Cash and Equivalents of $4.20 million for fiscal year 2023.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2023 | $4.20M | -21.5% |
| 2022 | $5.35M | +11.0% |
| 2021 | $4.82M | -4.8% |
| 2020 | $5.07M | +95.1% |
| 2019 | $2.60M | -39.2% |
| 2018 | $4.27M | +227.2% |
| 2017 | $1.31M | +553.1% |
| 2016 | $199.9K | +690.8% |
| 2015 | $25.3K | -43.1% |
| 2014 | $44.4K | -90.7% |
| 2013 | $475.0K | -71.3% |
| 2012 | $1.66M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| March 31, 2024 | $3.41M | -16.5% | -18.8% |
| December 31, 2023 | $4.20M | -21.5% | -17.7% |
| September 30, 2023 | $5.11M | -22.2% | +75.3% |
| June 30, 2023 | $2.91M | -62.3% | -28.7% |
| March 31, 2023 | $4.09M | +8.2% | -23.6% |
| December 31, 2022 | $5.35M | +11.0% | -18.4% |
| September 30, 2022 | $6.56M | +10.1% | -15.2% |
| June 30, 2022 | $7.74M | +13.8% | +104.8% |
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed a decrease of -21.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2023 period, LIXTE BIOTECHNOLOGY HOLDINGS, INC.’s cash and equivalents has grown by 154.0% (from $1.66 million to $4.20 million).
- The most recent figure is from LIXTE BIOTECHNOLOGY HOLDINGS, INC.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 19, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: